High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma

J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):135-41. doi: 10.1016/s0378-4347(99)00450-8.

Abstract

An HPLC assay was developed to determine the paclitaxel analogue 13-(N-tert.-butoxycarbonyl-beta-isobutylisoserinyl)-14-hydroxyb accatin-1,14-carbonate (IDN5109) and its epimer in mouse plasma. The method involves solid-phase extraction on cyano cartridges (recovery >75%), HPLC separation on symmetry shield column, a mobile phase of NaH2PO4 (10 mM) pH 5.2, acetonitrile (47:53) and detection at 227 nm. Retention times of IDN5109, its epiform and internal standard were 15, 24 and 25.5 min, respectively. The assay was linear from 0.10 to 10 microg/ml (r2 = 0.999), with a C.V. <5% and accuracy in the range of 95-107%. LOQ was 50 ng/ml for both compounds. Using this method IDN5109 pharmacokinetic was determined in mice.

MeSH terms

  • Animals
  • Bridged-Ring Compounds / blood*
  • Bridged-Ring Compounds / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods*
  • Drug Stability
  • Female
  • Freezing
  • Kinetics
  • Mice
  • Paclitaxel* / analogs & derivatives*
  • Quality Control
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Taxoids*

Substances

  • Bridged-Ring Compounds
  • Taxoids
  • IDN 5109
  • Paclitaxel